Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 7/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930022 | 1.00 | DGAT1 (0.42) | DGAT1NR1H2NR1H3HTR2CPRCP | |
| SCHEMBL825048 | 1.00 | DGAT1 (0.42) | DGAT1NR1H2NR1H3HTR2CPRCP | |
| SCHEMBL13145270 | 0.89 | DGAT1 (0.42) | DGAT1NR1H2NR1H3HTR2CPRCP | |
| SCHEMBL1293758 | 0.86 | LIPG (0.36) | DGAT1PRCPLIPGLPL | |
| SCHEMBL1294311 | 0.84 | USP30 (0.41) | DGAT1PRCP | |
| SCHEMBL20484364 | 0.84 | USP30 (0.41) | DGAT1PRCP | |
| SCHEMBL1294312 | 0.84 | USP30 (0.41) | DGAT1PRCP | |
| SCHEMBL19488464 | 0.84 | USP30 (0.41) | DGAT1PRCP | |
| SCHEMBL15773714 | 0.84 | USP30 (0.41) | DGAT1PRCP | |
| SCHEMBL20484365 | 0.84 | USP30 (0.41) | DGAT1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143301-B2 | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | DGAT1 811/4885NR1H2 156/4885NR1H3 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.